Should you buy Acadia Healthcare Company (ACHC)?
Updated
Acadia Healthcare has beaten earnings estimates in all four recent quarters, but the stock has essentially reached its near-term target with only 0.5% upside remaining, the underlying business generates negative free cash flow at roughly 6% of revenue, and 39% short interest reflects broad market skepticism about the fundamental outlook.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
With 57.7% of revenue derived from Medicaid, the business faces concentrated exposure to government reimbursement rates and policy decisions — any reduction in Medicaid funding or rate compression would materially impair revenues. Bear case | If commercial and self-pay revenue grows to represent more than 55% of total revenue within 12 months, the Medicaid concentration risk would diminish meaningfully. | →Stable |
| CounterMedicaid is a durable, counter-cyclical payer for behavioral health services; patients in these programs represent stable, recurring demand that is less susceptible to economic softness than commercial insurance payers. | ||
Free cash flow is negative at approximately 6% of revenue, meaning the business is consuming cash despite reporting positive net income — a structural quality gap that limits financial flexibility and raises questions about earnings sustainability. Quality breakdown | Free cash flow turns positive and represents at least 5% of revenue for 2 consecutive quarters. | →Stable |
| CounterA Piotroski F-Score of 8 out of 9 reflects broadly improving financial signals across the balance sheet; the negative free cash flow may reflect capital expenditures associated with capacity expansion that could drive future revenue growth. | ||
With only 0.5% headroom to the near-term price target and a reward-to-risk ratio of approximately 0.07-to-1, the stock is essentially priced at its near-term ceiling — there is no geometric entry case at current levels. Price targets | A reset to a higher analyst price target with upside exceeding 15% would need to emerge before a new entry becomes defensible. | →Stable |
| CounterStrong momentum with the stock above its 200-day moving average, a bullish MACD, and rising on-balance volume suggest the price could break above resistance and reset the target higher, potentially creating fresh upside. | ||
With 57.7% of revenue derived from Medicaid, the business faces concentrated exposure to government reimbursement rates and policy decisions — any reduction in Medicaid funding or rate compression would materially impair revenues.
→Stable- Expectation
- If commercial and self-pay revenue grows to represent more than 55% of total revenue within 12 months, the Medicaid concentration risk would diminish meaningfully.
CounterMedicaid is a durable, counter-cyclical payer for behavioral health services; patients in these programs represent stable, recurring demand that is less susceptible to economic softness than commercial insurance payers.
Free cash flow is negative at approximately 6% of revenue, meaning the business is consuming cash despite reporting positive net income — a structural quality gap that limits financial flexibility and raises questions about earnings sustainability.
→Stable- Expectation
- Free cash flow turns positive and represents at least 5% of revenue for 2 consecutive quarters.
CounterA Piotroski F-Score of 8 out of 9 reflects broadly improving financial signals across the balance sheet; the negative free cash flow may reflect capital expenditures associated with capacity expansion that could drive future revenue growth.
With only 0.5% headroom to the near-term price target and a reward-to-risk ratio of approximately 0.07-to-1, the stock is essentially priced at its near-term ceiling — there is no geometric entry case at current levels.
→Stable- Expectation
- A reset to a higher analyst price target with upside exceeding 15% would need to emerge before a new entry becomes defensible.
CounterStrong momentum with the stock above its 200-day moving average, a bullish MACD, and rising on-balance volume suggest the price could break above resistance and reset the target higher, potentially creating fresh upside.
▸ Show 1 more pillar▾ Show fewer
Short interest of 39% reflects deep market skepticism about the fundamental trajectory — at this level, short sellers are making a material and costly bet against the stock, typically signaling serious concerns about business quality or forward earnings visibility.
→Stable- Expectation
- Short interest declining to below 20% over 12 months would indicate that fundamental concerns are resolving and bears are covering.
CounterA 39% short position creates significant squeeze potential; if the business delivers consecutive earnings beats — as it has in recent quarters — forced short covering could produce an outsized price move even without fundamental improvement.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1With 57.7% of revenue derived from Medicaid, the business faces concentrated exposure to government reimbursement rates and policy decisions — any reduction in Medicaid funding or rate compression would materially impair revenues.
Trip ifMedicaid revenue falls below 45% of total revenue for 2 consecutive quarters.
- P2Free cash flow is negative at approximately 6% of revenue, meaning the business is consuming cash despite reporting positive net income — a structural quality gap that limits financial flexibility and raises questions about earnings sustainability.
Trip ifFree cash flow turns positive and exceeds 5% of revenue for 2 consecutive quarters.
- P3With only 0.5% headroom to the near-term price target and a reward-to-risk ratio of approximately 0.07-to-1, the stock is essentially priced at its near-term ceiling — there is no geometric entry case at current levels.
Trip ifPrice surpasses $30.00 and a new analyst consensus target above $35.00 establishes upside exceeding 15%.
- P4Short interest of 39% reflects deep market skepticism about the fundamental trajectory — at this level, short sellers are making a material and costly bet against the stock, typically signaling serious concerns about business quality or forward earnings visibility.
Trip ifShort interest falls below 20% within 12 months.
How the engine reached this verdict
TrendMatrix's engine output for Acadia Healthcare Company, Inc. (ACHC) is SELL_IF_HOLDING with medium conviction, score 5.6/10 at $25.41. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold. Co-failing gates ( ASYMMETRY:-0.1=NEGATIVE) reinforce the read; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.1>=5.5.
On the bear side: Concentration risk — Customer: Medicaid (57.7%); V8: Target reached (-1.2% upside); Quality below floor (3.4 < 4.0). Active engine warnings: V8: Target reached (-1.2% upside), Quality below floor (3.4 < 4.0), V9 Gate Failed: ASYMMETRY:-0.1=NEGATIVE.
The engine's exit framework anchors to a tactical sell band near $25.41, with structural invalidation at $23.64. The asymmetric R:R against a reversal hypothesis is 0.50 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ACHC — 10-dimension breakdown →
Bear case
- ▸Concentration risk — Customer: Medicaid (57.7%)
- ▸V8: Target reached (-1.2% upside)
- ▸Quality below floor (3.4 < 4.0)